Free Trial

Evaxion Biotech A/S Q3 2024 Earnings Report

Evaxion Biotech A/S logo
$0.92 +0.03 (+3.36%)
(As of 12/20/2024 05:31 PM ET)

Evaxion Biotech A/S EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Evaxion Biotech A/S Revenue Results

Actual Revenue
$3.02 million
Expected Revenue
$0.19 million
Beat/Miss
Beat by +$2.83 million
YoY Revenue Growth
N/A

Evaxion Biotech A/S Announcement Details

Quarter
Q3 2024
Time
N/A
Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Evaxion Biotech A/S Earnings Headlines

Evaxion Biotech pursues agreement with EIB to bolster equity
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Evaxion establishes new AI-derived precision cancer vaccine concept
See More Evaxion Biotech A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evaxion Biotech A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evaxion Biotech A/S and other key companies, straight to your email.

About Evaxion Biotech A/S

Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

View Evaxion Biotech A/S Profile

More Earnings Resources from MarketBeat

Upcoming Earnings